PFIZER INC (PFE) Stock Price & Overview

NYSE:PFE • US7170811035

Current stock price

26.58 USD
-0.28 (-1.04%)
At close:
26.64 USD
+0.06 (+0.23%)
After Hours:

The current stock price of PFE is 26.58 USD. Today PFE is down by -1.04%. In the past month the price decreased by -3.24%. In the past year, price increased by 3.34%.

PFE Key Statistics

52-Week Range20.915 - 27.94
Current PFE stock price positioned within its 52-week range.
1-Month Range26.2 - 27.94
Current PFE stock price positioned within its 1-month range.
Market Cap
151.141B
P/E
8.23
Fwd P/E
8.90
EPS (TTM)
3.23
Dividend Yield
6.46%

PFE Stock Performance

Today
-1.04%
1 Week
-1.74%
1 Month
-3.24%
3 Months
+2.82%
Longer-term
6 Months +11.35%
1 Year +3.34%
2 Years -4.22%
3 Years -34.85%
5 Years -26.64%
10 Years -10.32%

PFE Stock Chart

PFIZER INC / PFE Daily stock chart

PFE Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to PFE. When comparing the yearly performance of all stocks, PFE turns out to be only a medium performer in the overall market: it outperformed 53.18% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PFE Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to PFE. While PFE has a great profitability rating, there are quite some concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PFE Earnings

On February 3, 2026 PFE reported an EPS of 0.66 and a revenue of 17.56B. The company beat EPS expectations (14.29% surprise) and beat revenue expectations (2.56% surprise).

Next Earnings DateApr 27, 2026
Last Earnings DateFeb 3, 2026
PeriodQ4 / 2025
EPS Reported$0.66
Revenue Reported17.557B
EPS Surprise 14.29%
Revenue Surprise 2.56%

PFE Forecast & Estimates

35 analysts have analysed PFE and the average price target is 29.37 USD. This implies a price increase of 10.48% is expected in the next year compared to the current price of 26.58.

For the next year, analysts expect an EPS growth of -7.56% and a revenue growth -1.41% for PFE


Analysts
Analysts68.57
Price Target29.37 (10.5%)
EPS Next Y-7.56%
Revenue Next Year-1.41%

PFE Groups

Sector & Classification

PFE Financial Highlights

Over the last trailing twelve months PFE reported a non-GAAP Earnings per Share(EPS) of 3.23. The EPS increased by 3.86% compared to the year before.


Income Statements
Revenue(TTM)62.58B
Net Income(TTM)7.77B
Industry RankSector Rank
PM (TTM) 12.42%
ROA 3.73%
ROE 8.99%
Debt/Equity 0.71
Chartmill High Growth Momentum
EPS Q2Q%4.76%
Sales Q2Q%-1.16%
EPS 1Y (TTM)3.86%
Revenue 1Y (TTM)-1.64%

PFE Ownership

Ownership
Inst Owners67.65%
Shares5.69B
Float5.67B
Ins Owners0.02%
Short Float %2.58%
Short Ratio3.13

PFE Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LLY ELI LILLY & CO28.18921.899B
JNJ JOHNSON & JOHNSON20.74583.292B
MRK MERCK & CO. INC.22.34286.575B
BMY BRISTOL-MYERS SQUIBB CO9.33120.05B
ZTS ZOETIS INC16.3448.739B
RPRX ROYALTY PHARMA PLC- CL A8.8326.461B
VTRS VIATRIS INC5.3915.889B
ELAN ELANCO ANIMAL HEALTH INC21.8111.276B
AXSM AXSOME THERAPEUTICS INC N/A7.883B
BLTE BELITE BIO INC - ADR N/A6.361B
TERN TERNS PHARMACEUTICALS INC N/A4.698B
LGND LIGAND PHARMACEUTICALS23.94.217B

About PFE

Company Profile

PFE logo image Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

Company Info

IPO: 1944-01-17

PFIZER INC

66 Hudson Boulevard East

New York City NEW YORK 10017 US

CEO: Albert Bourla

Employees: 75000

PFE Company Website

PFE Investor Relations

Phone: 13026587581

PFIZER INC / PFE FAQ

What does PFIZER INC do?

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.


Can you provide the latest stock price for PFIZER INC?

The current stock price of PFE is 26.58 USD. The price decreased by -1.04% in the last trading session.


Does PFE stock pay dividends?

PFIZER INC (PFE) has a dividend yield of 6.46%. The yearly dividend amount is currently 1.72.


What is the ChartMill technical and fundamental rating of PFE stock?

PFE has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


What is the GICS sector and industry of PFE stock?

PFIZER INC (PFE) operates in the Health Care sector and the Pharmaceuticals industry.


Can you provide the PE ratio for PFE stock?

The PE ratio for PFIZER INC (PFE) is 8.23. This is based on the reported non-GAAP earnings per share of 3.23 and the current share price of 26.58 USD.


Can you provide the upcoming earnings date for PFIZER INC?

PFIZER INC (PFE) will report earnings on 2026-04-27.